Modality
Gene Therapy
MOA
MALT1i
Target
Cl18.2
Pathway
DDR
ADPKD
Development Pipeline
Preclinical
Aug 2020
→ Jan 2026
PreclinicalCurrent
NCT08153993
627 pts·ADPKD
2020-08→2026-01·Not yet recruiting
627 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-272mo agoInterim· ADPKD
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
Preclinical
Not yet…
Catalysts
Interim
2026-01-27 · 2mo ago
ADPKD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08153993 | Preclinical | ADPKD | Not yet recr... | 627 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 |